New Delhi, Feb. 16 -- After a decade of Lupin recovering in the corporate equivalent of an ICU, DBG (Desh Bandhu Gupta) did not mistake the consolation of having avoided disaster for good fortune. The decade since 1993 had been a public embarrassment, the balance sheet had been impaired and the company had been distracted. This had blunted Lupin's product momentum and sales aggression, causing it to drop out of the top ten Indian pharma companies. Ranbaxy and Lupin had similar sales in 1980; by 2003, it was three times larger. Despite the troubles receding by 2003, DBG knew that 'we do not learn from experience; we learn from reflecting on experience' and was ready to think honestly about the past to synthesize a new strategy..

DBG title...